- Oops!Something went wrong.Please try again later.
Data were presented at the Cold Spring Harbor Laboratory's Genome Engineering: CRISPR Frontiers meeting.
Editas' SLEEK platform enables high knock-in efficiencies with different transgenes while also ensuring robust, transgene expression.
New preclinical data demonstrated that SLEEK results in the knock-in of multiple clinically relevant transgenes through a proprietary process that selects for cells containing the knock-in cargo.
More than 90% knock-in efficiencies were observed in various clinically relevant target cells.
Additionally, SLEEK may be used to fine-tune the expression levels of transgene cargos, an essential attribute of next-generation cell therapy medicines.
Price Action: EDIT shares are up 7.44% at $64.87 during the premarket session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.